Cancer clinical trials in the region Occitanie

410 currently recruiting clinical trials
Region Occitanie
Phase 3 Breast cancer #NCT05633654
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy
Required previous treatments at advanced or metastatic stage
Surgery Chemotherapy Radiotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Antibody Drug Conjugates (ADC)
15 recruiting sites
Gilead Sciences
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT03534713
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma
Required FIGO stages
Stage I Stage II Stage III Stage IV
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy
11 recruiting sites
Hôpital universitaire de Toulouse
Phase 3 Cervical / Vulvar / Vaginal cancer #NCT05581121
Required histologic types
Cervical cancer
Required histologic sub types
Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma
Required FIGO stages
Stage III
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Radiotherapy
26 recruiting sites
Institut Claudius Regaud
Phase 3 Acute leukemia #NCT07007312 #2025-521314-25-00
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
KMT2A NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
17 recruiting sites
Kura Oncologie, Inc.
Phase 3 Acute leukemia #NCT07007312 #2025-521314-25-00
Required histologic types
Acute myeloid leukemia (AML)
Required genetic anomalies
NPM1
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
BCR-ABL
17 recruiting sites
Kura Oncologie, Inc.
Phase 3 Penile cancer and germ cell tumors #NCT05874063 #2022-502426-41-00
Required histologic types
Germ cell tumor
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required IGCCCG prognostic scores
Good prognosis Intermediate prognosis
18 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Breast cancer #NCT07237256 #2025-520979-13-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery
Excluded previous treatments at localized stage
Chemotherapy Targeted therapy
21 recruiting sites
UNICANCER
Phase 3 Breast cancer #NCT07085767 #2025-522873-12-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Olema Pharmaceuticals, Inc.
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06545955
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at localized stage
Surgery Immunotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
9 recruiting sites
Ferring Pharmaceuticals
Phase 3 Colon cancer Rectal cancer #NCT06662786 #2024-513852-13-00
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF HER2 KRAS G12C KRAS non G12C MSI/dMMR NRAS
7 recruiting sites
Janssen